Abstract

The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical trials based on cell engineering and adoptive cell therapies.
Its aims are as follows:
AIM1 : To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2 : GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks (plasmid DNA, cell banks).
AIM3 : Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability); Gene transfer/expression.
AIM4 : To monitor patients? samples post-infusion (e.g., FACS, Q-PCR).
AIM5 : To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084821
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Jakub, James W; Peled, Anne Warren; Gray, Richard J et al. (2018) Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg 153:123-129
Ulaner, Gary A; Lyashchenko, Serge K; Riedl, Christopher et al. (2018) First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med 59:900-906
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
McFarland, Daniel C; Shaffer, Kelly M; Tiersten, Amy et al. (2018) Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer. Psychosomatics 59:464-471
Aherne, Emily A; Plodkowski, Andrew J; Montecalvo, Joseph et al. (2018) What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? Lung Cancer 118:83-89
Perrin, Thomas; Midya, Abhishek; Yamashita, Rikiya et al. (2018) Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. Abdom Radiol (NY) 43:3271-3278
Apte, Aditya P; Iyer, Aditi; Crispin-Ortuzar, Mireia et al. (2018) Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys :
Santini, Fernando C; Rizvi, Hira; Plodkowski, Andrew J et al. (2018) Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 6:1093-1099
Ma, Jennifer; Setton, Jeremy; Lee, Nancy Y et al. (2018) The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun 9:3292

Showing the most recent 10 out of 8799 publications